DANBURY, Conn., June 4 /PRNewswire-FirstCall/ -- Biodel Inc. today announced that Gerard Michel, Chief Financial Officer, Vice President of Corporate Development and Treasurer of Biodel, will present a corporate update at the Canaccord Adams Diabetes and Obesity Conference on Friday, June 6, 2008 at 1:40 p.m. Pacific Daylight Time. The conference will be held at Hotel Nikko in San Francisco.
Interested parties may access a link to a live webcast of the corporate presentation in the investor relations section of Biodel’s website at www.biodel.com. An archive of the presentation will be available at the same location.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel’s product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. The Company’s lead product candidate, VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel’s pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company’s website at www.biodel.com.
BIOD-G
CONTACT: Investors, Rebecca Der, rder@burnsmc.com, or Media, Carney
Noensie, cnoensie@burnsmc.com, both of Burns McClellan, Inc.,
+1-212-213-0006, for Biodel Inc.
Web site: http://www.biodel.com/
